Aeglea BioTherapeutics entered into a biologics master services agreement with WuXi Biologics and a cell line license agreement, and regained compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market. Scott Burrows succeeded Jonathan Alspaugh as the company's CFO, and Alspaugh entered into a separation and consulting agreement with the company.